<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100045</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00090922</org_study_id>
    <nct_id>NCT03100045</nct_id>
  </id_info>
  <brief_title>Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)</brief_title>
  <acronym>ART-AIN</acronym>
  <official_title>A Phase I Study of Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Frantz Viral Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label study investigates a novel non-surgical approach to the treatment of
      HPV-associated anal intraepithelial neoplasia, using Artesunate suppositories.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients diagnosed with AIN 2/3 will be enrolled sequentially in treatment cohorts receiving
      different doses of Artesunate suppositories administered trans-anally. Doses of escalation
      will be 200 mg, 400 mg, and 600 mg. Treatment cohorts will consist of 2 or 3 cycles at each
      dose level. Suppositories will be administered daily for 5 days. Five days constitutes 1
      cycle. Up to 3 cycles will be administered at Weeks 0, 2, and 4.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Subjects will be enrolled sequentially in each treatment cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (Safety and tolerability) of Artesunate suppositories for the treatment of anal intraepithelial neoplasia (AIN2/3)</measure>
    <time_frame>6 weeks from the date of the first dosing</time_frame>
    <description>Number of patients with serious adverse events or dose limiting toxicities related to the study medication, according to CTCAE4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with histologic regression of anal intraepithelial neoplasia (AIN2/3) to AIN1 or less</measure>
    <time_frame>28 weeks</time_frame>
    <description>Number of patients with no AIN2/3 as assessed by high resolution anoscopy and biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with viral clearance of human papillomavirus (HPV) virus measured by HPV genotyping</measure>
    <time_frame>40 weeks</time_frame>
    <description>Number of patients with HPV genotypes present at study entry which become undetectable during the study window</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>HPV-Related Anal Intraepithelial Neoplasia</condition>
  <condition>AIN2/3</condition>
  <condition>Artesunate</condition>
  <condition>Alternative Treatment</condition>
  <condition>Anal Dysplasia</condition>
  <condition>Precancerous Conditions</condition>
  <condition>Human Papilloma Virus</condition>
  <arm_group>
    <arm_group_label>ART 200 mg, 2 cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two five-day cycles of Artesunate suppositories, 200 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART 200 mg, 3 cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three five-day cycles of Artesunate suppositories, 200 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART 400 mg, 2 cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two five-day cycles of Artesunate suppositories, 400 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART 400 mg, 3 cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three five-day cycles of Artesunate suppositories, 400 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART 600 mg, 2 cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two five-day cycles of Artesunate suppositories, 600 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ART 600 mg, 3 cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three five-day cycles of Artesunate suppositories, 600 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate Suppositories</intervention_name>
    <description>Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia</description>
    <arm_group_label>ART 200 mg, 2 cycles</arm_group_label>
    <arm_group_label>ART 200 mg, 3 cycles</arm_group_label>
    <arm_group_label>ART 400 mg, 2 cycles</arm_group_label>
    <arm_group_label>ART 400 mg, 3 cycles</arm_group_label>
    <arm_group_label>ART 600 mg, 2 cycles</arm_group_label>
    <arm_group_label>ART 600 mg, 3 cycles</arm_group_label>
    <other_name>Artemisinin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Biopsy-confirmed high-grade anal dysplasia (AIN 2, AIN 3, HSIL) by high resolution
             anoscopy (HRA)

          -  Female of childbearing potential: negative urine pregnancy test

          -  Able to provide informed consent

          -  Patients who have the ability to collaborate with planned follow-up (transportation,
             compliance history, etc.).

          -  Weight ≥50 kg.

        Exclusion Criteria:

          -  Diagnosis of low-grade anal dysplasia (AIN 1, LSIL) by high resolution anoscopy

          -  Known anal, vulvar, cervical, or penile cancer

          -  CD4 count &lt; 200 at the time of consideration for entry into this study

          -  Unable to provide informed consent

          -  Currently receiving systemic chemotherapy or radiation therapy for another cancer.

          -  Patients who are on medical treatment with systemic immunosuppressants or steroids
             (e.g., active autoimmune disease)

          -  Extensive anal condyloma precludes the ability for the clinician to visualize HSIL
             during HRA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandy H Fang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Cowell</last_name>
    <phone>410-955-7323</phone>
    <email>ncowell1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandy Fang</last_name>
    <phone>410-955-7323</phone>
    <email>sfang7@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandy Fang, MD</last_name>
      <phone>410-955-7323</phone>
      <email>sfang7@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Cowell</last_name>
      <email>ncowell1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sandy H Fang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evie Carchman, MD</last_name>
      <phone>608-263-1386</phone>
      <email>carchman@surgery.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katina DeShong, MPH</last_name>
      <phone>608-265-2493</phone>
      <email>deshong@wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Evie Carchman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>April 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>suppository</keyword>
  <keyword>Artesunate</keyword>
  <keyword>artemisinin</keyword>
  <keyword>anal dysplasia</keyword>
  <keyword>treatment</keyword>
  <keyword>alternative treatment</keyword>
  <keyword>anal precancer</keyword>
  <keyword>Johns Hopkins</keyword>
  <keyword>Sandy Fang</keyword>
  <keyword>Frantz Viral Therapeutics</keyword>
  <keyword>Wisconsin</keyword>
  <keyword>Evie Carchman</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

